<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897127</url>
  </required_header>
  <id_info>
    <org_study_id>AMLSG 30-18</org_study_id>
    <nct_id>NCT03897127</nct_id>
  </id_info>
  <brief_title>Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics</brief_title>
  <official_title>Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a randomized, open-label phase III study comparing CPX-351 vs conventional&#xD;
      intensive induction and consolidation chemotherapy in patients with newly diagnosed AML and&#xD;
      intermediate- or adverse-risk genetics (according to 2017 ELN criteria), including AML with&#xD;
      myelodysplasia-related changes (AML-MRC) and therapy-related AML according to the World&#xD;
      Health Organization (WHO) classification. Event-free survival (EFS) will be the primary&#xD;
      endpoint as defined by standard criteria (Döhner 2017).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival (RFS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death (CID)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of objective response</measure>
    <time_frame>2 months</time_frame>
    <description>complete remission [CR], CR with incomplete hematologic recovery [CRi], CR without minimal residual disease [CRMRD-]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>8 months</time_frame>
    <description>Incidence and intensity of adverse events (AEs) according to Common Terminology Criteria for Adverse Events (CTCAE) version v5.0</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Analysis of rate of response according to cytogenetic and molecular genetic changes</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Overall survival according to cytogenetic and molecular genetic changes</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Relapse-free survival according to cytogenetic and molecular genetic changes</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Event-free survival according to cytogenetic and molecular genetic changes</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Overall Survival according to Minimal Residual Disease results during and after treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of Event-free Survival according to Minimal Residual Disease results during and after treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL NCI PRO-CTCAE (National Cancer Institute) Patient Reported Outcomes Common Terminology Criteria for Adverse Events questionnaire)</measure>
    <time_frame>2 years</time_frame>
    <description>PRO-CTCAE responses are scored from 0 to 4, whereas lower values represent a better outcome. For this trial, the burden of symptoms that will be captured by this questionnaire comprises nausea, diarrhea, rash, and alopecia.</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL EORTC QLQ-FA12</measure>
    <time_frame>2 years</time_frame>
    <description>The EORTC QLQ-FA12 module complements the core EORTC QLQ-C30 questionnaire regarding fatigue. . Each item can be scored in four dimension on a scale from 1 to 4 with higher scores indicating worse symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>QoL EORTC QLQ-C30 (Core Quality of Life Questionnaire developed by European Organization for Research and Treatment of Cancer )</measure>
    <time_frame>2 years</time_frame>
    <description>The EORTC QLQ-C30 subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of hospitalization including admissions at intensive care unit (ICU)</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Reasons for hospitalization</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>days of hospitalization by treatment setting</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>rate of use of anti-infectives and other medications, e.g. against nausea or vomiting</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>additional therapies administered</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>place of chemotherapy administration (inpatient vs outpatient setting)</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>duration of administration</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>number of outpatient visits</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of salvage therapies</measure>
    <time_frame>8 months</time_frame>
    <description>Exploratory endpoint</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">593</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigational arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Induction therapy: 200 mg/m2 i.v. (continuously) d1-7&#xD;
Consolidation therapy:&#xD;
Patients age 18-60 years&#xD;
o Intermediate-dose cytarabine 1500 mg/m2 i.v. q12h (3 hrs) d1-3&#xD;
Patients age &gt;60 years o Intermediate-dose cytarabine 1000 mg/m2 i.v. q12h (3 hrs) d1-3</description>
    <arm_group_label>Standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Induction therapy: 60 mg/m2 i.v. (1 hr) d1-3</description>
    <arm_group_label>Standard arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>Induction 1:&#xD;
o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3,5&#xD;
Induction 2:&#xD;
o CPX-351 44 mg/m2 daunorubicin / 100 mg/m2 cytarabine [100 U/m²] i.v. (90 min) d1,3&#xD;
Consolidation therapy:&#xD;
o CPX-351 29 mg/m2 daunorubicin / 65 mg/m2 cytarabine [65 U/m²] i.v. (90 min) d1,3</description>
    <arm_group_label>Investigational arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with newly diagnosed AML and intermediate- or adverse-risk genetics&#xD;
             (according to 2017 ELN criteria [Appendix B]), including AML with&#xD;
             myelodysplasia-related changes (AML-MRC) and therapy-related AML according to the&#xD;
             World Health Organization (WHO) classification&#xD;
&#xD;
          2. Age ≥ 18 years, no upper age limit&#xD;
&#xD;
          3. Patient considered eligible for intensive chemotherapy&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 at Screening&#xD;
&#xD;
          5. Genetic assessment in AMLSG central laboratory&#xD;
&#xD;
          6. Adequate renal function as evidenced by serum creatinine ≤ 2.0 × ULN or creatinine&#xD;
             clearance &gt;40 mL/min based on the Cockcroft-Gault glomerular filtration rate (GFR)&#xD;
&#xD;
          7. Adequate hepatic function as evidenced by:&#xD;
&#xD;
               -  Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN) unless considered due&#xD;
                  to Gilbert's disease, or leukemic involvement following approval by the&#xD;
                  Coordinating Investigator or Co-Coordinating Investigator&#xD;
&#xD;
               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline&#xD;
                  phosphatase (ALP) ≤ 3.0 × ULN, unless considered due to leukemic involvement&#xD;
                  following approval by the Coordinating Investigator or Co-Coordinating&#xD;
                  Investigator&#xD;
&#xD;
          8. No prior chemotherapy for acute leukemia except hydroxyurea for up to 7 days during&#xD;
             the diagnostic screening phase for the control of peripheral leukemic blasts in&#xD;
             patients with leukocytosis (e.g., white blood cell [WBC] counts &gt;30x109/l); prior&#xD;
             treatment of myelo-dysplastic syndrome with hypomethylating agents is allowed&#xD;
&#xD;
          9. Non-pregnant and non-nursing women of childbearing potential (WOCBP) must have a&#xD;
             negative serum or urine pregnancy test within a sensitivity of at least 25 mIU/mL&#xD;
             within 72 hours prior to randomization (&quot;Women of childbearing potential&quot; is defined&#xD;
             as a sexually active mature woman who has not undergone a hysterectomy or bilateral&#xD;
             oophorectomy or who has had menses at any time in the preceding 24 consecutive months)&#xD;
&#xD;
         10. Female patients of childbearing potential must agree to avoid getting pregnant while&#xD;
             on therapy and for 6 months after the last dose of CPX-351&#xD;
&#xD;
         11. Women of childbearing potential must either commit to continued abstinence from&#xD;
             heterosexual intercourse or apply one highly effective method of birth control (such&#xD;
             as IUD, bilateral tubal ligation, or partner's vasectomy) in combination with one&#xD;
             acceptable method of birth control at the same time (such as hormonal contraception or&#xD;
             the male partner has to use a latex condom coated with spermicide lubricant or&#xD;
             combined with spermicide gel or foam) while on therapy and for 6 months after the last&#xD;
             dose of CPX-351. Hormonal contraception is only a highly effective method of birth&#xD;
             control in case of combined (estrogen and progestogen containing) associated with&#xD;
             inhibition of ovulation or progestogen-only hormonal contraception associated with&#xD;
             inhibition of ovulation is used&#xD;
&#xD;
         12. Men must use a latex condom coated with a spermicide lubricant or combined with&#xD;
             spermicide gel or foam during any sexual contact with women of childbearing potential,&#xD;
             even if they have undergone a successful vasectomy and must agree to avoid to father a&#xD;
             child (while on therapy and for 6 months after the last dose of CPX-351). In addition,&#xD;
             their female partners of childbearing potential have to use a highly effective method&#xD;
             of birth control&#xD;
&#xD;
         13. Able to understand and willing to sign an informed consent form (ICF)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. AML with favorable-risk genetics according to 2017 ELN criteria [Appendix B]:&#xD;
&#xD;
               -  AML with t(8;21)(q22;q22.1), RUNX1-RUNX1T1&#xD;
&#xD;
               -  AML with inv(16)(p13.1q22)/t(16;16)(p13.1;q22), CBFB-MYH11&#xD;
&#xD;
               -  AML with mutated NPM1 without FLT3-ITD or with FLT3-ITDlow&#xD;
&#xD;
               -  AML with biallelic CEBPA mutation&#xD;
&#xD;
          2. Acute promyelocytic leukemia (APL) with t(15;17)(q22;q12); PML-RARA; or one of the&#xD;
             other pathognomonic variant chromosomal translocations/ fusion genes&#xD;
&#xD;
          3. AML with BCR-ABL1&#xD;
&#xD;
          4. Prior treatment of myelodysplastic syndrome (MDS) with intensive chemotherapy or bone&#xD;
             marrow transplant with a curative intent&#xD;
&#xD;
          5. Significant active cardiac disease within 6 months prior to the start of study&#xD;
             treatment, including New York Heart Association (NYHA) class III or IV congestive&#xD;
             heart failure; myocardial infarction, unstable angina and/or stroke; severe cardiac&#xD;
             arrhythmias, or left ventricular ejection fraction (LVEF) &lt;50% by ultrasound obtained&#xD;
             within 28 days prior to the start of study treatment&#xD;
&#xD;
          6. Severe obstructive or restrictive ventilation disorder&#xD;
&#xD;
          7. Uncontrolled infection&#xD;
&#xD;
          8. Clinical symptoms suggestive of active central nervous system (CNS) leukemia or known&#xD;
             CNS leukemia. Evaluation of cerebrospinal fluid (CSF) during screening is only&#xD;
             required, if there is a clinical suspicion of CNS involvement by leukemia during&#xD;
             screening&#xD;
&#xD;
          9. Evidence of active hepatitis B or C infection or known Human Immunodeficiency Virus&#xD;
             (HIV) infection&#xD;
&#xD;
         10. Patients with a &quot;currently active&quot; second malignancy. Patients are not considered to&#xD;
             have a currently active malignancy, if they have completed therapy and are considered&#xD;
             by their physician to be at &lt; 30% risk of relapse within one year. However, subjects&#xD;
             with the following history/concurrent conditions are allowed:&#xD;
&#xD;
               -  Basal or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  Carcinoma in situ of the cervix&#xD;
&#xD;
               -  Carcinoma in situ of the breast&#xD;
&#xD;
               -  Incidental histologic finding of prostate cancer&#xD;
&#xD;
         11. Severe neurological or psychiatric disorder interfering with ability to give an&#xD;
             informed consent&#xD;
&#xD;
         12. No consent for registration, storage and processing of the individual disease&#xD;
             characteristics and course as well as information of the family physician about study&#xD;
             participation&#xD;
&#xD;
         13. No consent for biobanking of patient's biological specimens&#xD;
&#xD;
         14. Current participation in any other interventional clinical study within 30 days before&#xD;
             the first administration of the investigational product or at any time during the&#xD;
             study&#xD;
&#xD;
         15. Patients with prior cumulative anthracycline exposure of daunorubicin (or equivalent)&#xD;
             can be included but the maximum of daunorubicin (or equivalent) dose of 550 mg/m2 must&#xD;
             not be exceeded. In patients who received radiation therapy to the mediastinum the&#xD;
             maximum of daunorubicin (or equivalent) dose of 400 mg/m2 must not be exceeded.&#xD;
&#xD;
         16. Known or suspected hypersensitivity to cytarabine, daunorubicin or liposomal products&#xD;
             and/or any excipients&#xD;
&#xD;
         17. History of Wilson's disease or other copper-metabolism disorder&#xD;
&#xD;
         18. Receipt of live, attenuated vaccine within 30 days prior to the study inclusion (NOTE:&#xD;
             Subjects, if enrolled, should not receive live vaccine during the study and until 6&#xD;
             months after the therapy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Verena Gaidzik, MD</last_name>
    <phone>0049-731-500</phone>
    <phone_ext>45707</phone_ext>
    <email>verena.gaidzik@uniklinik-ulm.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Sill, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tirol Kliniken GmbH Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Nachbaur, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH, Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigrid Machherndl-Spandl, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Feldkirch, Landeskrankenhaus</name>
      <address>
        <city>Rankweil</city>
        <zip>6830</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hartmann, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Greil, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanuschkrankenhaus Wien</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Koller, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Welslau, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Simone Liebler, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Berlin Charite - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Westermann, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Philipp Le Coutre, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Uwe Pelzer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Am Urban</name>
      <address>
        <city>Berlin</city>
        <zip>10967</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Scholz, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Annette Dieing, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Berlin Charite - Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Westermann, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jan Krönke, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Klaus A Nogai, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Witt, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Lore Marretta, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Westermann, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Anne Flörcken, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Knappschaftskrankenhaus Bochum-Langendreer</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Schroers, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Deepak Ben Vangala, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teichmann Lino, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Katjana S Schwab, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig gGmbH</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Krauter, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Arne Trummer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Hertenstein, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephan Kaun, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Bernhard, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephan Schäfer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darina Kodzhabasheva, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ralf Georg Meyer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Germing, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kathrin Nachtkamp, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thomas Ulrych, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Süd, Ev. Krankenhaus Essen- Werden gGmbH</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Föhring, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Peter Reimer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Swen Wessendorf, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Guido Hausner, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Malteser Krankenhaus St. Franziskus-Hospital</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadezda Basara, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Helge Menzel, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lübbert, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Ralph Wäsch, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Burchardt, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mathias Rummel, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Katholisches Karl-Leisner-Klinikum gGmbH, Wilhelm-Anton-Hospital gGmbH Goch</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Runde, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jörn Westheider, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Heidel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Christian Späth, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asklepios Kliniken Hamburg GmbH St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmet Elmaagacli, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Anju Singh, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Fiedler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Winfried H Alsdorf, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Salwender, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Marcel Bernhardt, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Hamm gGmbH</name>
      <address>
        <city>Hamm</city>
        <zip>59063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Baraniskin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Andrea Stoltefuß, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andrea Stoltefuß, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Region Hannover - Klinikum Siloah</name>
      <address>
        <city>Hannover</city>
        <zip>30459</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Dörfel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Müller, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Kim Marienhagen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicitas Thol, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Michael Heuser, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>SLK-Kliniken GmbH Heilbronn</name>
      <address>
        <city>Heilbronn</city>
        <zip>74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Lindauer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Uwe Martens, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Marienhospital Herne, Klinikum der Ruhr</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Teipel, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Dirk Strumberg, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kaiserslautern, Westpfalz-Klinikum</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Held, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Milena Pfeifer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe gGmbH</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Ringhoffer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Lukas Kündgen, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Caritas-Krankenhaus Lebach</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Kremers, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Gero Leonhard-Helmschmidt, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Lippe-Lemgo</name>
      <address>
        <city>Lemgo</city>
        <zip>32657</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breuch Philipp, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Frank Hartmann, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Paschka, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>David Klank, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maxim Kebenko, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Tobias Bartscht</last_name>
    </contact_backup>
    <investigator>
      <last_name>Hellen Sievert, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Lüdenscheid</name>
      <address>
        <city>Lüdenscheid</city>
        <zip>58515</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Heil, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Iordanis Deligiannis, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Mikusko, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Vanja Zeremski, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johannes Gutenberg Universität</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kühn, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Markus Radsak, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klniikum Hochsauerland GmbH</name>
      <address>
        <city>Meschede</city>
        <zip>59872</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammad Wattad, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Barbara Wenning, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Joachim Tischler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Kai Wille, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharina Götze, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Katharina Nickel, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum, Offenburg-Gengenbach</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carsten Schwänen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Irmgard Dresel, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jochen Rentschler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Imme Conradi, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Frank Griesinger, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jochen Casper, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Andrea Renzelmann, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau</name>
      <address>
        <city>Passau</city>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Südhoff, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thorsten Nitsch, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Heudobler, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Hendrik Poeck, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Schleicher, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Lisa Pospiech, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Markus Knott, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marienhospital Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Denzlinger, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Lale Kaylkci, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Dietl, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas Kubin, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mutterhaus der Borromäerinnen</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Mahlberg, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stefan Heidel, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder Trier</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Kirchen, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Monika Lankeshofer-Loch, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximilian Christopeit, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Dominik Schneidawind, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Verena Gaidzik, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Hartmut Döhner, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum Villingen- Schwenningen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Graf La Rosée, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Martin Henkes, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Schostock, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Blasius Liss, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Verena Gaidzik</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>CPX-351</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

